Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled.

Klymenko Y, Nephew KP.

Cancers (Basel). 2018 Aug 30;10(9). pii: E295. doi: 10.3390/cancers10090295. Review.

2.

Changes in mRNA/protein expression and signaling pathways in in vivo passaged mouse ovarian cancer cells.

Cai Q, Fan Q, Buechlein A, Miller D, Nephew KP, Liu S, Wan J, Xu Y.

PLoS One. 2018 Jun 21;13(6):e0197404. doi: 10.1371/journal.pone.0197404. eCollection 2018.

3.

Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion.

Tang J, Pulliam N, Özeş A, Buechlein A, Ding N, Keer H, Rusch D, O'Hagan H, Stack MS, Nephew KP.

Mol Cancer Res. 2018 Aug;16(8):1226-1240. doi: 10.1158/1541-7786.MCR-17-0406. Epub 2018 May 14.

PMID:
29759990
4.

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.

Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, Lyons J, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP.

Clin Cancer Res. 2018 Jul 1;24(13):3163-3175. doi: 10.1158/1078-0432.CCR-18-0204. Epub 2018 Apr 3.

PMID:
29615458
5.

Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.

Özeş AR, Pulliam N, Ertosun MG, Yılmaz Ö, Tang J, Çopuroğlu E, Matei D, Özeş ON, Nephew KP.

Oncogene. 2018 Jun;37(26):3589-3600. doi: 10.1038/s41388-018-0218-z. Epub 2018 Mar 26.

6.

A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.

Matei D, Ghamande S, Roman L, Alvarez Secord A, Nemunaitis J, Markham MJ, Nephew KP, Jueliger S, Oganesian A, Naim S, Su XY, Keer H, Azab M, Fleming GF.

Clin Cancer Res. 2018 May 15;24(10):2285-2293. doi: 10.1158/1078-0432.CCR-17-3055. Epub 2018 Mar 2.

PMID:
29500276
7.

Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review.

Chovanec M, Taza F, Kalra M, Hahn N, Nephew KP, Spinella MJ, Albany C.

Target Oncol. 2018 Feb;13(1):49-60. doi: 10.1007/s11523-017-0546-x.

PMID:
29230671
8.

Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.

Fang F, Cardenas H, Huang H, Jiang G, Perkins SM, Zhang C, Keer HN, Liu Y, Nephew KP, Matei D.

Cancer Res. 2018 Feb 1;78(3):631-644. doi: 10.1158/0008-5472.CAN-17-1492. Epub 2017 Dec 11.

PMID:
29229600
9.

The novel ZIP4 regulation and its role in ovarian cancer.

Fan Q, Cai Q, Li P, Wang W, Wang J, Gerry E, Wang TL, Shih IM, Nephew KP, Xu Y.

Oncotarget. 2017 Sep 30;8(52):90090-90107. doi: 10.18632/oncotarget.21435. eCollection 2017 Oct 27.

10.

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.

MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A, Fleming GF, Mutch DG, Nephew KP, Wentzensen N, Goodfellow PJ, Dorigo O, Nijman HW, Broaddus R, Kohn EC.

Oncotarget. 2017 Aug 3;8(48):84579-84594. doi: 10.18632/oncotarget.19961. eCollection 2017 Oct 13. Review.

11.

A system for detecting high impact-low frequency mutations in primary tumors and metastases.

Anjanappa M, Hao Y, Simpson ER, Bhat-Nakshatri P, Nelson JB, Tersey SA, Mirmira RG, Cohen-Gadol AA, Saadatzadeh MR, Li L, Fang F, Nephew KP, Miller KD, Liu Y, Nakshatri H.

Oncogene. 2018 Jan 11;37(2):185-196. doi: 10.1038/onc.2017.322. Epub 2017 Sep 11.

12.

Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer.

Özeş AR, Wang Y, Zong X, Fang F, Pilrose J, Nephew KP.

Sci Rep. 2017 Apr 18;7(1):894. doi: 10.1038/s41598-017-00966-3.

13.

Subtype-specific CpG island shore methylation and mutation patterns in 30 breast cancer cell lines.

Chae H, Lee S, Nephew KP, Kim S.

BMC Syst Biol. 2016 Dec 23;10(Suppl 4):116. doi: 10.1186/s12918-016-0356-2.

14.

MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance.

Martin EC, Conger AK, Yan TJ, Hoang VT, Miller DF, Buechlein A, Rusch DB, Nephew KP, Collins-Burow BM, Burow ME.

FEBS Lett. 2017 Jan;591(2):382-392. doi: 10.1002/1873-3468.12538. Epub 2017 Jan 12.

15.

Complete Transcriptome RNA-Seq.

Miller DF, Yan P, Fang F, Buechlein A, Kroll K, Frankhouser D, Stump C, Stump P, Ford JB, Tang H, Michaels S, Matei D, Huang TH, Chien J, Liu Y, Rusch DB, Nephew KP.

Methods Mol Biol. 2017;1513:141-162.

PMID:
27807835
16.

Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation.

Conger AK, Martin EC, Yan TJ, Rhodes LV, Hoang VT, La J, Anbalagan M, Burks HE, Rowan BG, Nephew KP, Collins-Burow BM, Burow ME.

Noncoding RNA. 2016 Sep 21;2(3). pii: E8. doi: 10.3390/ncrna2030008.

17.

EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.

Cardenas H, Zhao J, Vieth E, Nephew KP, Matei D.

Oncotarget. 2016 Dec 20;7(51):84453-84467. doi: 10.18632/oncotarget.11497.

18.

BioVLAB-mCpG-SNP-EXPRESS: A system for multi-level and multi-perspective analysis and exploration of DNA methylation, sequence variation (SNPs), and gene expression from multi-omics data.

Chae H, Lee S, Seo S, Jung D, Chang H, Nephew KP, Kim S.

Methods. 2016 Dec 1;111:64-71. doi: 10.1016/j.ymeth.2016.07.019. Epub 2016 Jul 28.

PMID:
27477210
19.

Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer.

Milevskiy MJ, Al-Ejeh F, Saunus JM, Northwood KS, Bailey PJ, Betts JA, McCart Reed AE, Nephew KP, Stone A, Gee JM, Dowhan DH, Dray E, Shewan AM, French JD, Edwards SL, Clark SJ, Lakhani SR, Brown MA.

Hum Mol Genet. 2016 Aug 1;25(15):3269-3283. doi: 10.1093/hmg/ddw177. Epub 2016 Jul 4.

20.

Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.

Haley J, Tomar S, Pulliam N, Xiong S, Perkins SM, Karpf AR, Mitra S, Nephew KP, Mitra AK.

Oncotarget. 2016 May 31;7(22):32810-20. doi: 10.18632/oncotarget.9053.

21.

NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.

Özeş AR, Miller DF, Özeş ON, Fang F, Liu Y, Matei D, Huang T, Nephew KP.

Oncogene. 2016 Oct 13;35(41):5350-5361. doi: 10.1038/onc.2016.75. Epub 2016 Apr 4.

22.

Molecular determinants of chemotherapy resistance in ovarian cancer.

Cooley M, Fang P, Fang F, Nephew KP, Chien J.

Pharmacogenomics. 2015 Nov;16(16):1763-7. doi: 10.2217/pgs.15.130. Epub 2015 Nov 10. No abstract available. Erratum in: Pharmacogenomics. 2016 Mar;17(4):453. P Nephew, Kenneth [corrected to Nephew, Kenneth P].

23.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.

Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Review.

24.

Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.

Benson EA, Skaar TC, Liu Y, Nephew KP, Matei D.

PLoS One. 2015 Oct 20;10(10):e0141279. doi: 10.1371/journal.pone.0141279. eCollection 2015.

25.

Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1.

Rhodes LV, Tate CR, Hoang VT, Burks HE, Gilliam D, Martin EC, Elliott S, Miller DB, Buechlein A, Rusch D, Tang H, Nephew KP, Burow ME, Collins-Burow BM.

Oncogenesis. 2015 Oct 5;4:e168. doi: 10.1038/oncsis.2015.27.

26.

Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.

Rhodes LV, Martin EC, Segar HC, Miller DF, Buechlein A, Rusch DB, Nephew KP, Burow ME, Collins-Burow BM.

Oncotarget. 2015 Jun 30;6(18):16638-52.

27.

In vivo tumor growth of high-grade serous ovarian cancer cell lines.

Mitra AK, Davis DA, Tomar S, Roy L, Gurler H, Xie J, Lantvit DD, Cardenas H, Fang F, Liu Y, Loughran E, Yang J, Sharon Stack M, Emerson RE, Cowden Dahl KD, V Barbolina M, Nephew KP, Matei D, Burdette JE.

Gynecol Oncol. 2015 Aug;138(2):372-7. doi: 10.1016/j.ygyno.2015.05.040. Epub 2015 Jun 5.

28.

Hypermethylation of the TGF-β target, ABCA1 is associated with poor prognosis in ovarian cancer patients.

Chou JL, Huang RL, Shay J, Chen LY, Lin SJ, Yan PS, Chao WT, Lai YH, Lai YL, Chao TK, Lee CI, Tai CK, Wu SF, Nephew KP, Huang TH, Lai HC, Chan MW.

Clin Epigenetics. 2015 Jan 14;7:1. doi: 10.1186/s13148-014-0036-2. eCollection 2015.

29.

Stranded Whole Transcriptome RNA-Seq for All RNA Types.

Miller DF, Yan PX, Fang F, Buechlein A, Ford JB, Tang H, Huang TH, Burow ME, Liu Y, Rusch DB, Nephew KP.

Curr Protoc Hum Genet. 2015 Jan 20;84:11.14.1-23. doi: 10.1002/0471142905.hg1114s84.

30.

A mathematical model of bimodal epigenetic control of miR-193a in ovarian cancer stem cells.

Cheng FH, Aguda BD, Tsai JC, Kochańczyk M, Lin JM, Chen GC, Lai HC, Nephew KP, Hwang TW, Chan MW.

PLoS One. 2014 Dec 29;9(12):e116050. doi: 10.1371/journal.pone.0116050. eCollection 2014.

31.

Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.

Chen Z, Lan X, Thomas-Ahner JM, Wu D, Liu X, Ye Z, Wang L, Sunkel B, Grenade C, Chen J, Zynger DL, Yan PS, Huang J, Nephew KP, Huang TH, Lin S, Clinton SK, Li W, Jin VX, Wang Q.

EMBO J. 2015 Feb 12;34(4):502-16. doi: 10.15252/embj.201490306. Epub 2014 Dec 22.

32.

TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.

Cardenas H, Vieth E, Lee J, Segar M, Liu Y, Nephew KP, Matei D.

Epigenetics. 2014 Nov;9(11):1461-72. doi: 10.4161/15592294.2014.971608.

33.

MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer.

Zhang Y, Zhao FJ, Chen LL, Wang LQ, Nephew KP, Wu YL, Zhang S.

Oncotarget. 2014 Dec 15;5(23):12291-303.

34.

Global DNA methylation profiling technologies and the ovarian cancer methylome.

Tang J, Fang F, Miller DF, Pilrose JM, Matei D, Huang TH, Nephew KP.

Methods Mol Biol. 2015;1238:653-75. doi: 10.1007/978-1-4939-1804-1_34. Review.

PMID:
25421685
35.

Mg2+ effect on argonaute and RNA duplex by molecular dynamics and bioinformatics implications.

Nam S, Ryu H, Son WJ, Kim YH, Kim KT, Balch C, Nephew KP, Lee J.

PLoS One. 2014 Oct 17;9(10):e109745. doi: 10.1371/journal.pone.0109745. eCollection 2014.

36.

Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells.

Zhuang Y, Nguyen HT, Burow ME, Zhuo Y, El-Dahr SS, Yao X, Cao S, Flemington EK, Nephew KP, Fang F, Collins-Burow B, Rhodes LV, Yu Q, Jayawickramarajah J, Shan B.

Mol Carcinog. 2015 Dec;54(12):1656-67. doi: 10.1002/mc.22237. Epub 2014 Oct 18.

37.

The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.

Fang F, Munck J, Tang J, Taverna P, Wang Y, Miller DF, Pilrose J, Choy G, Azab M, Pawelczak KS, VanderVere-Carozza P, Wagner M, Lyons J, Matei D, Turchi JJ, Nephew KP.

Clin Cancer Res. 2014 Dec 15;20(24):6504-16. doi: 10.1158/1078-0432.CCR-14-1553. Epub 2014 Oct 14.

38.

microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.

Martin EC, Rhodes LV, Elliott S, Krebs AE, Nephew KP, Flemington EK, Collins-Burow BM, Burow ME.

Mol Cancer. 2014 Oct 6;13:229. doi: 10.1186/1476-4598-13-229.

39.

BioVLAB-MMIA-NGS: microRNA-mRNA integrated analysis using high-throughput sequencing data.

Chae H, Rhee S, Nephew KP, Kim S.

Bioinformatics. 2015 Jan 15;31(2):265-7. doi: 10.1093/bioinformatics/btu614. Epub 2014 Sep 29.

40.

Epigenetic targeting of ovarian cancer stem cells.

Wang Y, Cardenas H, Fang F, Condello S, Taverna P, Segar M, Liu Y, Nephew KP, Matei D.

Cancer Res. 2014 Sep 1;74(17):4922-36. doi: 10.1158/0008-5472.CAN-14-1022. Epub 2014 Jul 17.

41.

Effects of the endocrine-disrupting chemical DDT on self-renewal and differentiation of human mesenchymal stem cells.

Strong AL, Shi Z, Strong MJ, Miller DF, Rusch DB, Buechlein AM, Flemington EK, McLachlan JA, Nephew KP, Burow ME, Bunnell BA.

Environ Health Perspect. 2015 Jan;123(1):42-8. doi: 10.1289/ehp.1408188. Epub 2014 Jul 11.

42.

Decitabine reactivated pathways in platinum resistant ovarian cancer.

Fang F, Zuo Q, Pilrose J, Wang Y, Shen C, Li M, Wulfridge P, Matei D, Nephew KP.

Oncotarget. 2014 Jun 15;5(11):3579-89.

43.

Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer.

Wu D, Sunkel B, Chen Z, Liu X, Ye Z, Li Q, Grenade C, Ke J, Zhang C, Chen H, Nephew KP, Huang TH, Liu Z, Jin VX, Wang Q.

Nucleic Acids Res. 2014 Apr;42(6):3607-22. doi: 10.1093/nar/gkt1382. Epub 2014 Jan 13.

44.

Hypomethylation signature of tumor-initiating cells predicts poor prognosis of ovarian cancer patients.

Liao YP, Chen LY, Huang RL, Su PH, Chan MW, Chang CC, Yu MH, Wang PH, Yen MS, Nephew KP, Lai HC.

Hum Mol Genet. 2014 Apr 1;23(7):1894-906. doi: 10.1093/hmg/ddt583. Epub 2013 Nov 20.

45.

MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.

Antoon JW, Martin EC, Lai R, Salvo VA, Tang Y, Nitzchke AM, Elliott S, Nam SY, Xiong W, Rhodes LV, Collins-Burow B, David O, Wang G, Shan B, Beckman BS, Nephew KP, Burow ME.

PLoS One. 2013 Aug 9;8(8):e69291. doi: 10.1371/journal.pone.0069291. eCollection 2013.

46.

Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer.

Hsu PY, Hsu HK, Lan X, Juan L, Yan PS, Labanowska J, Heerema N, Hsiao TH, Chiu YC, Chen Y, Liu Y, Li L, Li R, Thompson IM, Nephew KP, Sharp ZD, Kirma NB, Jin VX, Huang TH.

Cancer Cell. 2013 Aug 12;24(2):197-212. doi: 10.1016/j.ccr.2013.07.007.

47.

Epithelial ovarian cancer experimental models.

Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS.

Oncogene. 2014 Jul 10;33(28):3619-33. doi: 10.1038/onc.2013.321. Epub 2013 Aug 12. Review.

48.

Integrated analysis of genome-wide DNA methylation and gene expression profiles in molecular subtypes of breast cancer.

Rhee JK, Kim K, Chae H, Evans J, Yan P, Zhang BT, Gray J, Spellman P, Huang TH, Nephew KP, Kim S.

Nucleic Acids Res. 2013 Oct;41(18):8464-74. doi: 10.1093/nar/gkt643. Epub 2013 Jul 24.

49.

3D culture adds an extra dimension to targeted epigenetic therapies.

Ozes AR, Nephew KP.

Cell Cycle. 2013 Jul 15;12(14):2173-4. No abstract available.

50.

Genome-wide analysis and modeling of DNA methylation susceptibility in 30 breast cancer cell lines by using CpG flanking sequences.

An J, Kim K, Rhee SM, Chae H, Nephew KP, Kim S.

J Bioinform Comput Biol. 2013 Jun;11(3):1341003. doi: 10.1142/S0219720013410035.

PMID:
23796180

Supplemental Content

Loading ...
Support Center